Business
Precision BioSciences Reports Fourth Quarter and Fiscal Year 2019 Financial Results and Provides Business Update
-Presented initial clinical data for lead allogeneic CAR T program PBCAR0191 for the treatment of NHL and B-ALL- -Implemented amendment to PBCAR0191 Phase
About this update from Precision Biosciences, Inc.
[{"type":"text","content":"-Presented initial clinical data for lead allogeneic CAR T program PBCAR0191 for the treatment of NHL and B-ALL-\n -Implemented amendment to PBCAR0191 Phase 1/2a trial focused on optimizing clinical activity, CAR T cell expansion and persistence- -Received FDA IND clearance and Orphan Drug Designation for two additional wholly-owned allogeneic CAR T programs targeting CD20 and BCMA; expect clinical trials to begin in 2020- -Announced first wholly-owned in vivo gene correction program targeting primary hyperoxaluria type 1 (PH1), a rare genetic disease; expect clinical candidate to be selected in 2020- -Achieved proof-of-concept for Elo Life Systems’ ZeroMelonTM zero calorie watermelon-based sweetener program; expect to move to greenhouse trials in 2020- DURHAM, N.C., March 10, 2020 (GLOBE NEWSWIRE) -- Precision BioSciences, Inc. (Nasdaq: DTIL) (“Precision”), a life sciences company dedicated to improving life through the application of its pioneering, proprietary ARCUS® genome editing platform, today announced financial results for the fourth quarter and fiscal year ended December 31, 2019, and provided a business update. “The considerable progress we made in 2019, our first year as a public company, positions Precision BioSciences to further accelerate development across all areas of our portfolio,” commented Matt Kane, CEO and co-founder of Precision BioSciences. “We now have three clinical-stage allogeneic CAR T candidates in development for the treatment of NHL, B-ALL, CLL/SLL and multiple myeloma, and have the clinical team and resources to focus on rapidly advancing these programs. We look forward to providing meaningful updates on their progress during 2020. Over the past year, we also built and opened our first-in-class cGMP-compliant manufacturing facility, advanced our partnered and wholly-owned in vivo gene-correction programs, and achieved validating milestones at our food-focused subsidiary, Elo Life Systems. I am very proud of the achievements of the entire Precision team in 2019 and am excited to continue this impressive pace of progress in 2020.” Recent Developments and Upcoming Milestones Allogeneic CAR T portfolio Presented initial clinical data for lead CD19-targeted allogeneic CAR T candidate PBCAR0191; dose escalation continuing on-track with further updates expected during 2020. IND applications cleared for...